These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 25263393

  • 21. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers.
    Robbins DK, Castles MA, Pack DJ, Bhargava VO, Weir SJ.
    Biopharm Drug Dispos; 1998 Oct; 19(7):455-63. PubMed ID: 9818712
    [Abstract] [Full Text] [Related]

  • 22. Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe.
    Zhou Q, Ye Z, Ruan Z, Zeng S.
    J Ethnopharmacol; 2013 Apr 19; 146(3):744-9. PubMed ID: 23422332
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
    Qiang F, Lee BJ, Lee W, Han HK.
    Eur J Pharm Sci; 2009 Jun 28; 37(3-4):413-7. PubMed ID: 19428223
    [Abstract] [Full Text] [Related]

  • 24. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
    Yamada S, Yasui-Furukori N, Akamine Y, Kaneko S, Uno T.
    Ther Drug Monit; 2009 Dec 28; 31(6):764-8. PubMed ID: 19855315
    [Abstract] [Full Text] [Related]

  • 25. Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects.
    Deng S, Chen XP, Cao D, Yin T, Dai ZY, Luo J, Tang L, Li YJ.
    Clin Ther; 2009 Jun 28; 31(6):1256-63. PubMed ID: 19695392
    [Abstract] [Full Text] [Related]

  • 26. Effect of fruit juices on the oral bioavailability of fexofenadine in rats.
    Kamath AV, Yao M, Zhang Y, Chong S.
    J Pharm Sci; 2005 Feb 28; 94(2):233-9. PubMed ID: 15570603
    [Abstract] [Full Text] [Related]

  • 27. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
    Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U, Lennernäs H.
    Clin Pharmacol Ther; 2003 Nov 28; 74(5):423-36. PubMed ID: 14586383
    [Abstract] [Full Text] [Related]

  • 28. Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates.
    Takahata T, Yasui-Furukori N, Yoshiya G, Uno T, Sugawara K, Tateishi T.
    Basic Clin Pharmacol Toxicol; 2004 May 28; 94(5):252-6. PubMed ID: 15125696
    [Abstract] [Full Text] [Related]

  • 29. Enantioselective uptake of fexofenadine by Caco-2 cells as model intestinal epithelial cells.
    Togami K, Tosaki Y, Chono S, Morimoto K, Hayasaka M, Tada H.
    J Pharm Pharmacol; 2013 Jan 28; 65(1):22-9. PubMed ID: 23215684
    [Abstract] [Full Text] [Related]

  • 30. The effect of rifampin administration on the disposition of fexofenadine.
    Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD.
    Clin Pharmacol Ther; 2001 Mar 28; 69(3):114-21. PubMed ID: 11240975
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
    Shimizu M, Uno T, Sugawara K, Tateishi T.
    Br J Clin Pharmacol; 2006 Sep 28; 62(3):372-6. PubMed ID: 16796706
    [Abstract] [Full Text] [Related]

  • 33. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.
    Clin Ther; 2010 Jun 28; 32(6):1188-204. PubMed ID: 20637971
    [Abstract] [Full Text] [Related]

  • 34. Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model.
    Pinto L, Bapat P, de Lima Moreira F, Lubetsky A, de Carvalho Cavalli R, Berger H, Lanchote VL, Koren G.
    Pharm Res; 2021 Apr 28; 38(4):647-655. PubMed ID: 33825113
    [Abstract] [Full Text] [Related]

  • 35. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
    Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD.
    Clin Pharmacol Ther; 2006 Mar 28; 79(3):218-30. PubMed ID: 16513446
    [Abstract] [Full Text] [Related]

  • 36. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
    Shimizu M, Uno T, Sugawara K, Tateishi T.
    Br J Clin Pharmacol; 2006 May 28; 61(5):538-44. PubMed ID: 16669847
    [Abstract] [Full Text] [Related]

  • 37. A modified grapefruit juice eliminates two compound classes as major mediators of the grapefruit juice-fexofenadine interaction: an in vitro-in vivo "connect".
    Won CS, Lan T, Vandermolen KM, Dawson PA, Oberlies NH, Widmer WW, Scarlett YV, Paine MF.
    J Clin Pharmacol; 2013 Sep 28; 53(9):982-90. PubMed ID: 23878024
    [Abstract] [Full Text] [Related]

  • 38. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.
    Yamazaki A, Kumagai Y, Yamane N, Tozuka Z, Sugiyama Y, Fujita T, Yokota S, Maeda M.
    J Clin Pharm Ther; 2010 Apr 28; 35(2):169-75. PubMed ID: 20456735
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.